Myelofibrosis
Italiano
The FDA issued an update on the recommendations about the potential for exposure to airborne chemicals from neonatal incubators.
This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program
Dans le traitement de la dermatite atopique modérée ou grave chez le patient de 12 ans ou plus admissible à un traitement à action générale.
80.211.154.110